Sarcomas and transitional cell carcinomas are not included
  • American Joint Committee on Cancer

Summary of Changes

T2 lesions have been divided to include T2a, T2b, and T2c once again. These are the same subcategories found in the Fourth Edition of the manual.

Gleason score is emphasized as the grading system of choice and using the terms well differentiated, moderately differentiated, and poorly differentiated for grading is not recommended.


Prostate Cancer Radical Prostatectomy Gleason Score Adenoid Cystic Carcinoma Localize Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aihara M, Wheeler TM, Ohori M, et al: Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43:60–67, 1994PubMedCrossRefGoogle Scholar
  2. Albertsen PC, Fryback DG, Storer BE, et al: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626–631, 1995PubMedCrossRefGoogle Scholar
  3. Albertsen PC, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, Stanford JL, Stephenson RA: The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population-based analysis. J Urol 163(4):1138–1143, 2000PubMedCrossRefGoogle Scholar
  4. Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280(11):975–980, 1998PubMedCrossRefGoogle Scholar
  5. Bazinet M, Meshref AW, Trudel C, Aronson S, et al: Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 43:44–52, 1994PubMedCrossRefGoogle Scholar
  6. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Was-son J, Zietman A, Thompson I: Prostate-specific antigen best practice policy. Part II: Prostate cancer staging and post-treatment follow-up. Urology 57:225–229, 2001PubMedCrossRefGoogle Scholar
  7. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ: Digital rectal examination for detecting prostate cancer at prostate-specific antigen levels of 4 ng/ml or less. J Urol 161(3):835–839, 1999PubMedCrossRefGoogle Scholar
  8. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate-specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152:2037–2042, 1994PubMedGoogle Scholar
  9. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160(6 Pt 2):2428–2434, 1998PubMedGoogle Scholar
  10. Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248, 1994PubMedCrossRefGoogle Scholar
  11. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate-specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2):2407–2411, 1998PubMedGoogle Scholar
  12. Epstein JI, Partin, AW, Sauvageot, J, and Walsh, PC: Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Amer J Surg Path, 20:286, 1996CrossRefGoogle Scholar
  13. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:3582–3593, 1993PubMedCrossRefGoogle Scholar
  14. Ferguson JK, Bostwick DG, Suman V, et al: Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors. Eur Urol 27:8–12, 1995PubMedGoogle Scholar
  15. Grignon DJ, Hammond EH: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch Pathol Lab Med 119, December 1995Google Scholar
  16. Han M, Walsh PC, Partin AW, Rodriguez R: Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for Stage T2 disease. J Urol 164(l):89–92, 2000PubMedGoogle Scholar
  17. Henson DE, Hutter RV, Farrow G: Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 118:779–783, 1994PubMedGoogle Scholar
  18. Humphrey PA, Frazier HA, Vollmer RT, et al: Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer 71:1822–1827, 1992Google Scholar
  19. McNeal JE, Villers AA, Redwine EA, et al: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66:1225–1233, 1990PubMedCrossRefGoogle Scholar
  20. Miller GJ: New developments in grading prostate cancer. Semin Urol 8:9–18, 1990PubMedGoogle Scholar
  21. Montie JE: Staging of prostate cancer: current TNM classifications and future prospects for prognostic factors. Cancer Supplement 75:1814–1818, 1995CrossRefGoogle Scholar
  22. Optenberg SA, Clark JY, Brawer MK, Thompson IM, Stein CR, Friedrichs P. Development of a decision-making tool to predict risk of prostate cancer: The Cancer of the Prostate Risk Index (CAPRI) Test. Urology 50:665–672, 1997Google Scholar
  23. Partin AW, Oesterling JE: The clinical usefulness of prostate-specific antigen: update 1994. J Urol 152:1358–1368, 1994PubMedGoogle Scholar
  24. Pinover WH, Hanlon A, Lee WR, et al: Prostate carcinoma patients upstaged by imaging and treated with irradiation—an outcome-based analysis. Cancer 77(7):1334–1341, 1996PubMedCrossRefGoogle Scholar
  25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281(17):1591–1597, 1999PubMedCrossRefGoogle Scholar
  26. Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ: Clinical and pathological characteristics, and recurrence rates of Stage T1c versus T2a or T2b prostate cancer. J Urol 161(5):1525–1529, 1999PubMedCrossRefGoogle Scholar
  27. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, et al: Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. N Engl J Med 323:621–625, 1990PubMedCrossRefGoogle Scholar
  28. Simon R, Altman DG: Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69:979–985, 1994PubMedCrossRefGoogle Scholar
  29. Smith DS, Catalona WJ: Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45:70–74, 1995PubMedCrossRefGoogle Scholar
  30. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG: Prediction of post-radical prostatectomy pathological outcome for Stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162(4):1346–1351, 1999PubMedCrossRefGoogle Scholar
  31. Terris MK, McNeal JE, Freiha FS, et al: Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol 149:1035–1039, 1993PubMedGoogle Scholar
  32. Zagars GK, von Eschenbach AC: Prostate-specific antigen—an important marker for prostate cancer treated by external beam radiation therapy. Cancer 72:538–548, 1993PubMedCrossRefGoogle Scholar
  33. Zincke H, Bergstrahl EJ, Blute ML, et al: Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 12:2254–2263, 1994PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • American Joint Committee on Cancer
    • 1
  1. 1.Executive OfficeChicagoUSA

Personalised recommendations